OBJECTIVE: Both the diagnosis and treatment of bipolar disorder in youth remain the subject of debate. In the Treatment of Early Age Mania (TEAM) study, risperidone was more effective than lithium or divalproex in children diagnosed with bipolar mania and highly comorbid with attention-deficit/hyperactivity disorder (ADHD). We searched for treatment moderators and predictors of outcome. METHOD: TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase. Outcome measures included binary end-of-treatment responder status and change in the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) Mania Rating Scale (KMRS). Baseline demographics and clinical characteristics were tested as modifiers of treatment effect and as overall predictors of outcome. RESULTS: Moderator effects were detected for site, ADHD, and obesity. Across sites, the response ratio (RR) for risperidone versus lithium ranged from 1.2 (95% confidence interval [CI] = 0.8-1.7) to 8.3 (95% CI = 1.1-60.8), and for risperidone versus divalproex from 1.3 (95% CI = 0.8-2.2) to 10.5 (95% CI = 1.4-77.7). The RR for risperidone versus lithium was 2.1 for patients with ADHD, but 1.0 for those without ADHD, and 2.3 (95% CI = 1.6-3.3) for nonobese patients, but 1.1 (95% CI = 0.6-2.0) for obese ones. Older age and less severe ADHD symptoms were associated with greater improvement on the KMRS. CONCLUSIONS:Risperidone was more effective than lithium or divalproex across the demographics and clinical characteristics of the sample, but the magnitude of its effect was influenced by site-related characteristics and presence of ADHD. Clinical trial registration information--Treatment of Early Age Mania; http://clinicaltrials.gov/; NCT00057681.
RCT Entities:
OBJECTIVE: Both the diagnosis and treatment of bipolar disorder in youth remain the subject of debate. In the Treatment of Early Age Mania (TEAM) study, risperidone was more effective than lithium or divalproex in children diagnosed with bipolar mania and highly comorbid with attention-deficit/hyperactivity disorder (ADHD). We searched for treatment moderators and predictors of outcome. METHOD: TEAM was a multi-site, 8-week, randomized clinical trial of risperidone, lithium, or divalproex in 279 medication-naïve patients, aged 6 through 15 years, with a DSM-IV diagnosis of bipolar disorder currently in manic or mixed phase. Outcome measures included binary end-of-treatment responder status and change in the Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS) Mania Rating Scale (KMRS). Baseline demographics and clinical characteristics were tested as modifiers of treatment effect and as overall predictors of outcome. RESULTS: Moderator effects were detected for site, ADHD, and obesity. Across sites, the response ratio (RR) for risperidone versus lithium ranged from 1.2 (95% confidence interval [CI] = 0.8-1.7) to 8.3 (95% CI = 1.1-60.8), and for risperidone versus divalproex from 1.3 (95% CI = 0.8-2.2) to 10.5 (95% CI = 1.4-77.7). The RR for risperidone versus lithium was 2.1 for patients with ADHD, but 1.0 for those without ADHD, and 2.3 (95% CI = 1.6-3.3) for nonobese patients, but 1.1 (95% CI = 0.6-2.0) for obese ones. Older age and less severe ADHD symptoms were associated with greater improvement on the KMRS. CONCLUSIONS:Risperidone was more effective than lithium or divalproex across the demographics and clinical characteristics of the sample, but the magnitude of its effect was influenced by site-related characteristics and presence of ADHD. Clinical trial registration information--Treatment of Early Age Mania; http://clinicaltrials.gov/; NCT00057681.
Authors: Barbara Geller; Joan L Luby; Paramjit Joshi; Karen Dineen Wagner; Graham Emslie; John T Walkup; David A Axelson; Kristine Bolhofner; Adelaide Robb; Dwight V Wolf; Mark A Riddle; Boris Birmaher; Nasima Nusrat; Neal D Ryan; Benedetto Vitiello; Rebecca Tillman; Philip Lavori Journal: Arch Gen Psychiatry Date: 2012-01-02
Authors: Barbara Geller; James L Craney; Kristine Bolhofner; Michael J Nickelsburg; Marlene Williams; Betsy Zimerman Journal: Am J Psychiatry Date: 2002-06 Impact factor: 18.112
Authors: B Geller; K Bolhofner; J L Craney; M Williams; M P DelBello; K Gundersen Journal: J Am Acad Child Adolesc Psychiatry Date: 2000-12 Impact factor: 8.829
Authors: Andrea Cipriani; Corrado Barbui; Georgia Salanti; Jennifer Rendell; Rachel Brown; Sarah Stockton; Marianna Purgato; Loukia M Spineli; Guy M Goodwin; John R Geddes Journal: Lancet Date: 2011-08-16 Impact factor: 79.321
Authors: Danella M Hafeman; Brian Rooks; John Merranko; Fangzi Liao; Mary Kay Gill; Tina R Goldstein; Rasim Diler; Neal Ryan; Benjamin I Goldstein; David A Axelson; Michael Strober; Martin Keller; Jeffrey Hunt; Heather Hower; Lauren M Weinstock; Shirley Yen; Boris Birmaher Journal: J Am Acad Child Adolesc Psychiatry Date: 2019-07-29 Impact factor: 8.829
Authors: A Peters; L G Sylvia; P V da Silva Magalhães; D J Miklowitz; E Frank; M W Otto; N S Hansen; D D Dougherty; M Berk; A A Nierenberg; T Deckersbach Journal: Psychol Med Date: 2014-04-10 Impact factor: 7.723
Authors: Rebecca F McKnight; Saïk J G N de La Motte de Broöns de Vauvert; Edward Chesney; Ben H Amit; John Geddes; Andrea Cipriani Journal: Cochrane Database Syst Rev Date: 2019-06-01
Authors: S L McElroy; D E Kemp; E S Friedman; N A Reilly-Harrington; L G Sylvia; J R Calabrese; D J Rabideau; T A Ketter; M E Thase; V Singh; M Tohen; C L Bowden; E E Bernstein; B D Brody; T Deckersbach; J H Kocsis; G Kinrys; W V Bobo; M Kamali; M G McInnis; A C Leon; S Faraone; A A Nierenberg; R C Shelton Journal: Acta Psychiatr Scand Date: 2015-06-26 Impact factor: 6.392
Authors: Ryan S Sultan; Christoph U Correll; Michael Schoenbaum; Marrisa King; John T Walkup; Mark Olfson Journal: J Child Adolesc Psychopharmacol Date: 2018-01-29 Impact factor: 2.576
Authors: Jay A Salpekar; Paramjit T Joshi; David A Axelson; Shauna P Reinblatt; Gayane Yenokyan; Abanti Sanyal; John T Walkup; Benedetto Vitiello; Joan L Luby; Karen Dineen Wagner; Nasima Nusrat; Mark A Riddle Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-10-08 Impact factor: 8.829
Authors: Gagan Joshi; Carter Petty; Janet Wozniak; Stephen V Faraone; Andrea E Spencer; K Yvonne Woodworth; Rachel Shelley-Abrahamson; Hannah McKillop; Stephannie L Furtak; Joseph Biederman Journal: Psychopharmacology (Berl) Date: 2013-02-09 Impact factor: 4.530
Authors: Regina Sala; Michael A Strober; David A Axelson; Mary Kay Gill; Josefina Castro-Fornieles; Tina R Goldstein; Benjamin I Goldstein; Wonho Ha; Fangzi Liao; Satish Iyengar; Shirley Yen; Heather Hower; Jeffrey Hunt; Daniel P Dickstein; Neal D Ryan; Martin B Keller; Boris Birmaher Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-10-17 Impact factor: 8.829